Viral structural protein antigen

Viral structural protein antigens form the physical architecture of viruses, including capsids that protect the genome, envelope glycoproteins like hemagglutinin or spike proteins that mediate host cell attachment and entry via receptor binding and membrane fusion, matrix proteins that bridge nucleocapsids to membranes, and nucleoproteins that encapsidate viral RNA or DNA. These proteins are highly immunogenic, serving as key targets for host antibodies and T-cell responses that neutralize infectivity or mark virions for destruction. In disease, they drive pathogenesis by facilitating replication cycles—such as SARS-CoV-2 spike enabling ACE2 binding or Flavivirus NS1 promoting vascular leakage—and enable immune evasion through mutations that alter epitopes, as seen in emerging variants. While direct small-molecule drugs are rare due to their extracellular roles and high mutability, monoclonal antibodies (e.g., targeting SARS-CoV-2 RBD) and vaccines elicit responses against them to prevent infection. Challenges include antigenic drift, requiring broad-spectrum approaches, and potential risks like antibody-dependent enhancement where non-neutralizing antibodies worsen disease. Overall, they represent prime vaccine antigens but indirect therapeutic targets compared to viral enzymes.

Other names

viral structural proteinviral antigenviral capsid proteinviral envelope proteinviral matrix proteinviral nucleoproteinspike protein (SARS-CoV-2)hemagglutinin-esterase protein (ISAV)NS1 (Flavivirus)

Neutralizing antibodies block receptor binding or fusion. Entry inhibitors disrupt host receptor interactions.